Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOLUTION-Pilot: Tirzepatide in Obesity-related Hypertension
NCT07364175Recruiting
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Jan 2026
- Primary completion
- Jan 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of tirzepatide in hypertension (HTN) and obesity (2 arms), sponsored by Cambridge University Hospitals NHS Foundation Trust. Primary endpoint: Ambulatory systolic blood pressure at 24 weeks. Started Jan 2026; status: recruiting.
02
Drugs
03
Conditions
hypertension (HTN)obesity
Beyond the preview
Go deeper on NCT07364175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07364175.